Brevio« Nerve Conduction Testing System

Coverage decision

The Brevio® Nerve Conduction Testing System is not covered at this time. L&I reviewed the scientific literature and determined there is not sufficient evidence of efficacy for this diagnostic tool. Brevio® is considered investigational and experimental.

This coverage decision applies to all State Fund and self-insured claims in all locations.


The NeuMed Brevio is a handheld device intended for use in evaluating nerve function. Similar to conventional nerve conduction study devices, the Brevio® assesses function via surface electrodes. This evidence does not support the accuracy or reliability of Nervepace for use as a diagnostic or screening tool for any condition(s) and specifically for carpal tunnel syndrome.

Billing information

Nerve conduction tests performed with Brevio® do not have unique billing codes at this time. The manufacturer of Brevio® recommends use of CPT codes:

  • 95900,
  • 95903,
  • 95904.

These codes apply to billing for motor nerve testing, motor nerve testing with F-waves and sensory nerve testing.

Note: These codes are approved only for nerve conduction studies performed with traditional nerve conduction testing systems.

In accordance with WAC 296-20-03002, L&I will not pay for treatment which is considered experimental in nature. L&I may recoup payments plus interest for nerve conduction tests paid inappropriately.

For more information:
Brevio® Assessment (24 KB PDF)

WAC 296-20-02704 - What criteria does the director or director's designee use to make medical coverage decisions?
WAC 296-20-02850 - When may L&I cover controversial, obsolete, investigational or experimental treatment?

Contact information.

End of main content, page footer follows.

Access Washington official state portal

   © Washington State Dept. of Labor & Industries. Use of this site is subject to the laws of the state of Washington.

Help us improve